Five-year mortality and morbidity impact of prolonged versus brief ICU stay: a propensity score matched cohort study.


Journal

Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353

Informations de publication

Date de publication:
11 2019
Historique:
received: 23 12 2018
revised: 03 06 2019
accepted: 26 06 2019
pubmed: 5 9 2019
medline: 19 5 2020
entrez: 5 9 2019
Statut: ppublish

Résumé

Long-term outcomes of critical illness may be affected by duration of critical illness and intensive care. We aimed to investigate differences in mortality and morbidity after short (<8 days) and prolonged (≥8 days) intensive care unit (ICU) stay. Former EPaNIC-trial patients were included in this preplanned prospective cohort, 5-year follow-up study. Mortality was assessed in all. For morbidity analyses, all long-stay and-for feasibility-a random sample (30%) of short-stay survivors were contacted. Primary outcomes were total and post-28-day 5-year mortality. Secondary outcomes comprised handgrip strength (HGF, %pred), 6-minute-walking distance (6MWD, %pred) and SF-36 Physical Function score (PF SF-36). One-to-one propensity-score matching of short-stay and long-stay patients was performed for nutritional strategy, demographics, comorbidities, illness severity and admission diagnosis. Multivariable regression analyses were performed to explore ICU factors possibly explaining any post-ICU observed outcome differences. After matching, total and post-28-day 5-year mortality were higher for long-stayers (48.2% (95%CI: 43.9% to 52.6%) and 40.8% (95%CI: 36.4% to 45.1%)) versus short-stayers (36.2% (95%CI: 32.4% to 40.0%) and 29.7% (95%CI: 26.0% to 33.5%), p<0.001). ICU risk factors comprised hypoglycaemia, use of corticosteroids, neuromuscular blocking agents, benzodiazepines, mechanical ventilation, new dialysis and the occurrence of new infection, whereas clonidine could be protective. Among 276 long-stay and 398 short-stay 5-year survivors, HGF, 6MWD and PF SF-36 were significantly lower in long-stayers (matched subset HGF: 83% (95%CI: 60% to 100%) versus 87% (95%CI: 73% to 103%), p=0.020; 6MWD: 85% (95%CI: 69% to 101%) versus 94% (95%CI: 76% to 105%), p=0.005; PF SF-36: 65 (95%CI: 35 to 90) versus 75 (95%CI: 55 to 90), p=0.002). Longer duration of intensive care is associated with excess 5-year mortality and morbidity, partially explained by potentially modifiable ICU factors. NCT00512122.

Identifiants

pubmed: 31481633
pii: thoraxjnl-2018-213020
doi: 10.1136/thoraxjnl-2018-213020
doi:

Banques de données

ClinicalTrials.gov
['NCT00512122']

Types de publication

Comparative Study Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1037-1045

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Greet Hermans (G)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium Greet.Hermans@uzleuven.be.
Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.

Nathalie Van Aerde (N)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Philippe Meersseman (P)

Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.

Helena Van Mechelen (H)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Yves Debaveye (Y)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium.

Alexander Wilmer (A)

Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium.

Jan Gunst (J)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium.

Michael Paul Casaer (MP)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium.

Jasperina Dubois (J)

Department of Anaesthesia and Intensive Care Medicine, Jessa Hospitals, Hasselt, Belgium.

Pieter Wouters (P)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.

Rik Gosselink (R)

Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium.

Greet Van den Berghe (G)

Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
Department of Anaesthesia and Intensive Care Medicine, Jessa Hospitals, Hasselt, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH